Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Resmed Inc (RMD)

Resmed Inc (RMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is ResMed Stock Underperforming the S&P 500?

With a market cap of $37.4 billion, San Diego, California-based ResMed Inc. (RMD) develops and markets medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders worldwide. The company operates through two segments: Sleep and Breathing Health, and Residential Care Software, offering solutions ranging from sleep diagnostics and therapy devices to comprehensive healthcare software platforms. 

Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and ResMed fits this criterion perfectly. Its innovations include portable diagnostic tools, cloud-based monitoring systems, and enterprise software solutions supporting sleep clinics, home medical equipment providers, and senior care organizations.

Fundamentals

See More
  • Market Capitalization, $K 37,441,160
  • Shares Outstanding, K 145,941
  • Annual Sales, $ 5,146 M
  • Annual Income, $ 1,401 M
  • EBIT $ 1,792 M
  • EBITDA $ 2,028 M
  • 60-Month Beta 0.87
  • Price/Sales 7.13
  • Price/Cash Flow 22.45
  • Price/Book 6.00

Options Overview Details

View History
  • Implied Volatility 26.08% (-0.27%)
  • Historical Volatility 21.00%
  • IV Percentile 30%
  • IV Rank 15.76%
  • IV High 56.66% on 04/08/25
  • IV Low 20.36% on 08/13/25
  • Expected Move (DTE 11) 8.93 (3.53%)
  • Put/Call Vol Ratio 22.00
  • Today's Volume 23
  • Volume Avg (30-Day) 1,337
  • Put/Call OI Ratio 4.39
  • Today's Open Interest 25,708
  • Open Int (30-Day) 26,830
  • Expected Range 243.87 to 261.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.67
  • Number of Estimates 5
  • High Estimate 2.74
  • Low Estimate 2.62
  • Prior Year 2.43
  • Growth Rate Est. (year over year) +9.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
237.63 +6.38%
on 12/01/25
258.09 -2.05%
on 11/28/25
+1.30 (+0.52%)
since 11/07/25
3-Month
237.63 +6.38%
on 12/01/25
284.87 -11.26%
on 10/08/25
-26.67 (-9.54%)
since 09/08/25
52-Week
199.92 +26.45%
on 04/07/25
293.81 -13.96%
on 08/22/25
+11.38 (+4.71%)
since 12/06/24

Most Recent Stories

More News
Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received...

RMD.AX : 38.410 (-1.03%)
RMD : 252.14 (-1.72%)
Is ResMed Stock Underperforming the S&P 500?

Though ResMed has lagged behind the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.

$SPX : 6,847.19 (-0.34%)
RMD : 252.14 (-1.72%)
ISRG : 563.99 (-1.97%)
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Headwinds

1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Headwinds

RMD : 252.14 (-1.72%)
NEOG : 6.07 (+1.51%)
CBSH : 52.52 (+0.54%)
Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know

Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know

CORT : 85.07 (-1.21%)
ELAN : 21.88 (-0.09%)
LMAT : 83.94 (-0.70%)
PEN : 295.28 (-1.79%)
RMD : 252.14 (-1.72%)
Are Wall Street Analysts Predicting ResMed Stock Will Climb or Sink?

ResMed has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

$SPX : 6,847.19 (-0.34%)
RMD : 252.14 (-1.72%)
IHI : 62.40 (-1.70%)
1 Large-Cap Stock to Target This Week and 2 We Brush Off

1 Large-Cap Stock to Target This Week and 2 We Brush Off

STT : 123.36 (-0.20%)
DHI : 154.35 (-2.69%)
RMD : 252.14 (-1.72%)
1 S&P 500 Stock to Research Further and 2 We Turn Down

1 S&P 500 Stock to Research Further and 2 We Turn Down

BF.B : 29.87 (-1.74%)
RMD : 252.14 (-1.72%)
URI : 794.41 (-0.31%)
ResMed’s Q3 Earnings Call: Our Top 5 Analyst Questions

ResMed’s Q3 Earnings Call: Our Top 5 Analyst Questions

RMD : 252.14 (-1.72%)
RMD Q3 Deep Dive: ResMed Launches New Mask Platform and Invests in U.S. Operations

RMD Q3 Deep Dive: ResMed Launches New Mask Platform and Invests in U.S. Operations

RMD : 252.14 (-1.72%)
ResMed: Fiscal Q1 Earnings Snapshot

ResMed: Fiscal Q1 Earnings Snapshot

RMD : 252.14 (-1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory...

See More

Key Turning Points

3rd Resistance Point 261.80
2nd Resistance Point 259.89
1st Resistance Point 258.22
Last Price 252.14
1st Support Level 254.64
2nd Support Level 252.73
3rd Support Level 251.06

See More

52-Week High 293.81
Fibonacci 61.8% 257.94
Last Price 252.14
Fibonacci 50% 246.86
Fibonacci 38.2% 235.79
52-Week Low 199.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar